Acousia Therapeutics
Latest round
- Series B
Last raised
- May 2018
Total raised
- $14M
Investors
- 6
About Acousia Therapeutics
a. Acousia Therapeutics is a biotechnology company that focuses on finding and developing novel compounds that can be used to prevent and treat patients suffering from sensorineural hearing loss (SNHL). The company’s first clinical study of ACOU085 for age-related hearing loss is underway following approval from the German Federal Institute for Drugs and Medical Devices.
Who invested in Acousia Therapeutics
6 investors across 2 rounds
See all investors in Acousia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Acousia Therapeutics
Who invested in Acousia Therapeutics?
Acousia Therapeutics has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Acousia Therapeutics raised?
Acousia Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Acousia Therapeutics last raise money?
Acousia Therapeutics's most recent round on record is a Series B, in May 2018.
What does Acousia Therapeutics do?
Acousia Therapeutics is a biotechnology company.
Where is Acousia Therapeutics headquartered?
Acousia Therapeutics is headquartered in Germany.
Which VCs invest in companies like Acousia Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Acousia Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Acousia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.